Italia markets closed

EDIT Aug 2024 10.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,39000,0000 (0,00%)
In data: 10:36AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente4,3900
Aperto4,3900
Denaro4,2000
Domanda4,7000
Prezzo d'esercizio10,00
Scadenza2024-08-16
Min-Max giorno4,3900 - 4,3900
Contratto - Min-MaxN/D
Volume6
Open Interest202
  • GlobeNewswire

    Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

    CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene editing medicine, for the treatment of severe sickle cell disease (SCD). “Sickle cell disease is a devastating disease that leads to anemia, pain crises, organ failure, and early death. Receiving RMAT

  • GlobeNewswire

    Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

    CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Commercial and Strategy Officer, Caren Deardorf. In connection with Ms. Deardorf’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Ms. Deardorf as an inducement material to Ms. Deardorf entering into employment with Editas Medicine in accordan

  • GlobeNewswire

    Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

    Caren Deardorf Editas Medicine, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support a